
Ranbaxy Laboratories Ltd January-March net loss at Rs 74 crore
Ranbaxy Laboratories Ltd, which is being acquired by Sun Pharmaceuticals for $3.2 billion, on Friday reported a consolidated net loss of about Rs 74 crore for the fourth quarter ended March 31, 2014 against a net profit of Rs 126 crore in the year-ago quarter due to a rise in finance costs and write-offs related to regulatory sanctions.
Total income fell 1.7% to Rs 2,491 crore during the quarter.
The company has changed its financial year from January -December to April-March effective April 1 2014. The current financial year is for a period of 15 months — January 1, 2013 to March 31, 2014 and, accordingly, the figures for the fifteen months ended March 31, 2014 are not comparable with the figures for the year ended December 31, 2012.
The Daiichi Sankyo-owned firm made a provision of Rs 63 crore during the quarter for inventory write-offs and other costs related to the ban. It also made a provision of Rs 70 crore for impairment of goodwill in subsidiaries and reduction in the value of an investment in an associate.
The company said cost of foreign currency borrowing rose to Rs 114 crore during the quarter from Rs 53 crore a year ago.
"Despite multiple challenges, Ranbaxy met its sales guidance and continued to build on its strengths. At the same time we continue to work closely with the regulatory agencies to address their concerns," said Arun Sawhney, CEO & managing director, Ranbaxy Laboratories.
"Ranbaxy posted numbers below expectations. However, the company met its annual sales guidance of Rs 13,000 crore for 2013-14," said Sarabjit Kour Nangra, pharma analyst, Angel Broking.
(with agency inputs)

Jack Ma Emerges for First Time Since Crackdown on Ant, Alibaba

Sensex rallies over 170 points in early trade; Nifty tops 14,590

IRFC IPO closes today, was oversubscribed 1.22 times on Tuesday

Supreme Court upholds laws protecting new owners of bankrupt companies

Siddhartha Mohanty appointed as new LIC MD

Hopes of new US stimulus, liquidity drive up markets

Govt’s infra push drives up project tenders in Q3

Govt may not reduce excise duty on fuel soon: Official

Bank of America’s trading unit falls short of rivals during bumper year

Goldman Sachs profit more than doubles on underwriting, trading boost

Investor wealth zooms ₹3.41 lakh crore as markets witness massive buying

Sebi extends relaxations for compliance with rights issues

India to contribute 15% of global growth by FY26: Report

Withdraw privacy policy updates: What Centre said in its letter to WhatsApp CEO
